Quick Takeaways
- OKUR - OnKure Therapeutics, Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q1 2026.
- Headline metric: Return On Equity -74%.
- Info
- Insider Trading
- Financials
- Holders
OnKure Therapeutics, Inc. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2026.
- Symbol
- OKUR on Nasdaq
- Location
- Boulder, CO
- Fiscal year end
- 31 December
- Latest financial report
- 12 Mar 2026
What Changed
- Return On Equity YoY change: <span class="text-red-600">-99%</span>.
- Most recent SEC facts end date: 11 Mar 2026.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Official SEC Source
Based on latest 10-Q/10-K
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original FilingLatest SEC snapshot (2026-03-11) highlights Return On Equity -74.4%, Return On Assets -67.2%, and Current Ratio 10.28x.
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
21.6/100
Weak Confidence medium
Return On Equity
-74%
Metric score 0.0/100
Return On Assets
-67%
Metric score 0.0/100
Financial Health
- Current Ratio
- 10.28x
- Debt to Equity
- 0.1x
Strengths
Debt-to-equity
Watchpoints
Return On Equity, Return On Assets, and Current Ratio
Key metrics snapshot
Return On Equity
-74%
YoY: -99%
Industry median: -43% (n=671)
Return On Assets
-67%
YoY: -3.8%
Industry median: -48% (n=669)
Current Ratio
10.28x
YoY: -4.3%
Industry median: 3.39x (n=667)
Debt-to-equity
0.1x
YoY: -235%
Industry median: 0.28x (n=634)
NetIncomeLoss YoY
-13%
YoY:
Industry median: -0.54% (n=641)
Profitability
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | -74% | -99% |
| Return On Assets | -67% | -3.8% |
Financial Health
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 10.28x | -4.3% |
| Debt-to-equity | 0.1x | -235% |
Growth
| Metric | Latest value | YoY change |
|---|---|---|
| NetIncomeLoss YoY | -13% |
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 13,673,565 |
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY